Skip to main content
. 2019 Apr 15;2019:2928507. doi: 10.1155/2019/2928507

Figure 2.

Figure 2

The XRD (a) and DSC (b) characterization of PAC, HMHA, PM, PAC-MHA, and PAC-HMHA. PAC, paclitaxel; HMHA, hyaluronic acid functionalized mesoporous hollow alumina nanoparticles; PM, the physical mixture of the drug and HMHA; PAC-MHA, paclitaxel-mesoporous hollow alumina nanoparticles; PAC-HMHA, paclitaxel-hyaluronic acid functionalized mesoporous hollow alumina nanoparticles.